期刊文献+

外泌体在甲状腺癌的研究进展 被引量:2

Research progress of exosomes in thyroid cancers
原文传递
导出
摘要 外泌体是一种直径50~140 nm的细胞外囊泡,包含DNA、RNA、蛋白质等多种内容物,几乎来源于所有类型的细胞。外泌体存在于血液、乳汁、尿液,通过传递生物活性分子在细胞间通讯中起着关键作用。论文综述外泌体的概况、功能及应用,总结外泌体miRNAs和circRNAs对甲状腺癌的影响及作为一种新型生物标志物的潜能。 The exosome are extracellular vesicle with a diameter of 50-140 nm, generated by almost all types of cell and carrying nucleic acids, proteins, lipids, and metabolites. They are found in all biological fluids such as blood, milk, urine etc.and play a key role in intercellular communication by delivering active biomolecules. This paper rviews the general situation, functions and applications of exosomes, summarize the effects of exosomal miRNAs and circRNAs in thyroid carcinoma and the potential as a new type of biomarkers.
作者 张轶轶(综述) 薛刚(审校) 金春亭(审校) ZHANG Yiyi;XUE Gang;JIN Chunting(Basic Medical College,Hebei North University,Zhangjiakou075000,Hebei,China;Department of Otorhinolaryngology&Head and Neck Surgery,The First Affiliated Hospital of Hebei North University,Zhangjia-kou075061,Hebei,China;Department of Pathology,Hebei North University,Zhangjiakou075000,Hebei,China)
出处 《山东大学耳鼻喉眼学报》 CAS 2021年第2期131-135,共5页 Journal of Otolaryngology and Ophthalmology of Shandong University
基金 河北省财政厅专科能力建设和专科带头人培养项目(361009) 张家口市科技计划项目(1911019D)。
关键词 甲状腺癌 外泌体 细胞外囊泡 微小RNA 生物标志物 Thyroid cancers Exosome Extracellular vesicles MicroRNAs(miRNA) Biomarkers
  • 相关文献

参考文献6

二级参考文献24

  • 1Swiemiak M, Wojcicka A, Czetwertynska M, et al. In- depth characterization of the microRNA transcriptome in normal thyroid and papillary thyroid carcinoma[ J]. J Clin Endocrinol Metab. , 2013, 98 (8) : 1401-1409.
  • 2Network CGAR: Integrated genomic characterization of papillary thyroid carcinoma [ J]. Cell, 2014, 159 ( 3 ) : 676 -690.
  • 3Qiu J, Zhang W W, Xia Q S, et al. RNA Sequencing identifies crucial genes in papillary thyroid carcinoma (PTC) progression[ J]. Exp Mol Pathol, 2016, 100( 1 ) : 151-159.
  • 4Kushchayeva Y, Jensen K, Burman J K, et al. Reposi- tioning therapy for thyroid cancer: new insights on estab- lished medications [ J]. Endocr Relat Cancer, 2014, 21 (3) :183-194.
  • 5Essig G F Jr, Porter K, Schneider D, et al. Fine needle aspiration and medullary thyroid carcinoma: the risk of in-adequate preoperative evaluation and initial surgery when relying upon FNAB cytology alone [ J ]. Endocr Pract, 2013, 19(6):920-927.
  • 6Trimboli P, Seregni E, Treglia G, et al. Procalcitonin for detecting medullary thyroid carcinoma: a systematic re- view[J]. Endocr Relat Cancer, 2015, 22(3) :157-164.
  • 7Pazaitou-Panayiotou K, Chrisoulidou A, Mandanas S, et al. Predictive factors that influence the course of medul- lary thyroid carcinoma[J]. Int J Clin Oncol, 2014, 19 (3) :445-451.
  • 8Barbet J, Campion L, Kraeber-Bodere F, et al. Prognos- tic impact of serum calcitonin and carcinoembryonic anti- gen doubing-times in patients with medullary thyroid car- cinoma[ J]. J Clin Endocrinol Metab, 2005, 90 ( 11 ) : 6077-6084.
  • 9Bugalho M J, Santos J R, Sobrinho L. Preoperative diag- nosis of medullary thyroid carcinoma: fine needle aspira- tion cytology as compared with serum calcitonin measure- ment[ J]. J Surg Oncol, 2005, 91(1 ) :56-60.
  • 10Camacho C P, Lindsey S C, Melo M C, et al. Measure- ment of calcitonin and calcitonin gene-related peptide mRNA refines the management of patients with medullar- y thyroid cancer and may replace calcitonin-stimulation tests [ J ]. Thyroid, 2013, 23 (3) :308-316.

共引文献33

同被引文献14

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部